Posts with tag AI

According to a common quip in the U.S. they innovate on the technology front, and the Europeans innovate on the regulatory front. It has been argued that regulating AI with more emphasis on risks than on innovation is a common European theme so far, especially with the AI Act on the horizon. In this context it is interesting to observe and compare how regulatory bodies in the U.S. and Europe position themselves. For the pharmaceutical sector, the U.S. Food and Drug Administration (“FDA”) and the...